Streetbeat News

Analyst Ratings

MDB

MongoDB (NASDAQ:MDB) has received 17 analyst ratings in the last quarter, with 16 being bullish or somewhat bullish and 1 being bearish. The average price target is $443.0, indicating an upside from the current price of $328.0. This average has increased by 7.92% from the previous average price target of $410.50.

Portfolio Pulse from Benzinga Insights

October 06, 2023 | 5:00 pm

VRTS

Over the past 3 months, 5 analysts have published somewhat bearish opinions on Virtus Inv (NASDAQ:VRTS) stock. The average price target is $164.0, implying a downside from the current price of $193.85. This average has increased by 3.27% from the previous average price target of $158.80.

Portfolio Pulse from Benzinga Insights

October 06, 2023 | 5:00 pm

OMC

Over the past 3 months, 6 analysts have published their opinion on Omnicom Group (NYSE:OMC) stock. The analysts have an average price target of $100.17 versus the current price of Omnicom Group at $72.91, implying upside. This current average has decreased by 3.84% from the previous average price target of $104.17.

Portfolio Pulse from Benzinga Insights

October 06, 2023 | 5:00 pm

STEM

Piper Sandler has maintained its Neutral rating for Stem (NYSE:STEM) but lowered its price target from $5.00 to $4.00. Stem's shares are currently trading down 2.43% at $3.62 per share. A move to $4.00 would represent a 10.5% increase from the current share price.

Portfolio Pulse from Benzinga Insights

October 06, 2023 | 5:00 pm

VEL

Citigroup has maintained its Neutral rating for Velocity Financial (NYSE:VEL) but lowered its price target from $14.00 to $13.00. Velocity Financial's shares are currently trading at $11.34, and a move to $13.00 would represent a 14.64% increase.

Portfolio Pulse from Benzinga Insights

October 06, 2023 | 5:00 pm

PEP

The CNBC Halftime Report discussed PepsiCo, potentially impacting the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 4:59 pm

AMGN

MRTX

SNY

Sanofi SA is reportedly considering the acquisition of Mirati Therapeutics Inc, which could strengthen Sanofi's drug pipeline and reduce its reliance on asthma medicine Dupixent. This would also aid Mirati in commercializing Krazati and funding further studies. Mirati's Krazati received FDA accelerated approval in December, but European regulators issued a negative opinion. Meanwhile, FDA advisers concluded that data from a late-stage trial lacked the requisite reliability to endorse the traditional approval of Amgen Inc's Lumakras. Analysts believe this could provide a positive boost to Krazati's launch and short-term adoption rate.

Portfolio Pulse from Vandana Singh

October 06, 2023 | 4:44 pm

PANW

A whale investor has taken a bullish stance on Palo Alto Networks (NASDAQ:PANW), with 62% of investors opening trades with bullish expectations and 37% with bearish. The whale has been targeting a price range from $210.0 to $450.0 for Palo Alto Networks over the last 3 months. The price of PANW is currently down -0.7% at $235.12. HSBC has downgraded its action to Hold with a price target of $242, while Citigroup and BTIG maintain their Buy rating with price targets of $285 and $292 respectively.

Portfolio Pulse from Benzinga Insights

October 06, 2023 | 4:30 pm

COF

A whale investor has taken a bullish stance on Capital One Financial (NYSE:COF), with 63% of the investors opening trades with bullish expectations and 36% with bearish. The whale has been targeting a price range from $92.0 to $110.0 for Capital One over the last 3 months. Citigroup maintains a Buy rating on Capital One with a price target of $126, while Morgan Stanley maintains an Underweight rating with a price target of $86.

Portfolio Pulse from Benzinga Insights

October 06, 2023 | 4:30 pm

IQ

OTR Global has upgraded iQIYI (NASDAQ:IQ) from Mixed to Positive.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 4:30 pm